Drug Trial Radar · NCT06462118
A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jan 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jun 17, 2024
Primary completion
Oct 22, 2024
Study completion Oct 22, 2024
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective is to study how astegolimab may behave in the body when injected subcutaneously into the abdomen, thigh, or upper arm in healthy participants.
Conditions
- Healthy Volunteers
Interventions
AstegolimabDrug
Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the curve from Hour 0 to the time of last measurable concentration (AUC0-t) of astegolimabTime frame: Approximately 85 days
- AUC extrapolated to infinity (AUC0-infinity) of astegolimabTime frame: Approximately 85 days
- Maximum serum concentration (Cmax) of astegolimabTime frame: Approximately 85 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Covance Research Unit - Daytona
Daytona Beach, Florida
Covance Research Unit - Dallas
Dallas, Texas
Covance Clinical Research Unit, Inc
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.